Surrozen (SRZN) Net Income (2020 - 2026)
Surrozen (SRZN) posted quarterly Net Income of -$32.5 million for Q1 2026, down 126.42% year-over-year from $123.0 million in Q1 2025, and down 259.1% quarter-over-quarter from -$9.1 million in Q4 2025.
Surrozen (SRZN) Net Income (2020 - 2026) Analysis & Trends
Surrozen's Net Income history runs 7 years deep, the most recent figure standing at -$32.5 million for Q1 2026.
- In Q1 2026, Net Income fell 126.42% year-over-year to -$32.5 million; the TTM figure through Mar 2026 stood at -$76.6 million (up 10.05% YoY), while the FY2025 annual figure was -$51.9 million, up 31.43% from the prior year.
- Net Income for Q1 2026 stood at -$32.5 million, down from -$9.1 million in the prior quarter.
- The five-year high for Net Income was $104000.0 in Q3 2024, with the low at -$60.1 million in Q4 2024.
- The 5-year median for Net Income is -$14.7 million (2023), against an average of -$17.5 million.
- The sharpest annual moves came in 2024 and 2025: Net Income surged 100.71% in 2024, then plunged 17616.35% in 2025.
- Surrozen's Net Income stood at -$1.7 million in 2022, then plunged by 443.05% to -$9.2 million in 2023, then tumbled by 551.78% to -$60.1 million in 2024, then surged by 84.94% to -$9.1 million in 2025, then plunged by 259.1% to -$32.5 million in 2026.
- Business Quant data shows SRZN's Net Income at -$32.5 million in Q1 2026, -$9.1 million in Q4 2025, and -$18.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | -26.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.52 Mn |
| Mar 31, 2026 | -32.50 Mn |
| Dec 31, 2025 | -9.05 Mn |
| Sep 30, 2025 | -18.22 Mn |
| Jun 30, 2025 | -16.82 Mn |
| Mar 31, 2025 | -14.36 Mn |
| Dec 31, 2024 | -60.10 Mn |
| Sep 30, 2024 | 104,000.00 |
| Jun 30, 2024 | -10.79 Mn |
| Mar 31, 2024 | -11.65 Mn |
| Dec 31, 2023 | -9.22 Mn |
| Sep 30, 2023 | -14.75 Mn |
| Jun 30, 2023 | -14.52 Mn |
| Mar 31, 2023 | -19.57 Mn |
| Dec 31, 2022 | -1.70 Mn |
| Sep 30, 2022 | -20.20 Mn |
| Jun 30, 2022 | -21.44 Mn |
| Mar 31, 2022 | -22.62 Mn |
| Dec 31, 2021 | -15.05 Mn |
| Sep 30, 2021 | -23.23 Mn |